NLSP
Income statement / Annual
Last year (2024), NLS Pharmaceutics AG's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, NLS Pharmaceutics AG's net income was -$1.98 M.
See NLS Pharmaceutics AG,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$3.32 K
|
$11.41 K
|
$11.41 K
|
$10.05 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
-$3.32 K
|
-$11.41 K
|
-$11.41 K
|
-$10.05 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$422.05 K
|
$5.91 M
|
$8.98 M
|
$5.92 M
|
$99.58 K
|
$1.70 M
|
$708.46
|
$4.32 M
|
| General & Administrative Expenses |
$3.21 M
|
$5.90 M
|
$6.51 K
|
$5.94 K
|
$2.20 K
|
$3.30 M
|
$2.74 K
|
$1.44 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$6.49 M
|
$5.93 M
|
$2.20 M
|
$2.49 M
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$3.21 M
|
$5.90 M
|
$6.49 M
|
$5.93 M
|
$2.20 M
|
$2.49 M
|
$2.74 K
|
$1.44 M
|
| Other Expenses |
$743.84 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$4.38 M
|
$11.81 M
|
$15.47 M
|
$11.85 M
|
$2.30 M
|
$4.20 M
|
$3.45 K
|
$5.77 M
|
| Cost And Expenses |
$4.38 M
|
$11.81 M
|
$15.48 M
|
$11.86 M
|
$2.30 M
|
$4.20 M
|
$3.45 K
|
$5.77 M
|
| Interest Income |
$0.00
|
$0.00
|
$100.87
|
$68.13
|
$233.70
|
$819.71
|
$0.00
|
$890.40
|
| Interest Expense |
$150.02 K
|
$145.15 K
|
$100.87 K
|
$68.13 K
|
$233.70 K
|
$819.71 K
|
$1.08 K
|
$890.40 K
|
| Depreciation & Amortization |
$3.32 K
|
$11.41 K
|
$11.41 K
|
$10.05 K
|
$0.00
|
$4.20 M
|
$3.45 K
|
$5.77 M
|
| EBITDA |
-$3.63 M |
-$11.80 M |
-$15.47 M |
-$11.85 M |
-$2.63 M |
-$430.40 K |
$0.00 |
-$5.77 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$2.40 M
|
-$364.97 K
|
-$1.01 M
|
-$85.46 K
|
-$562.07 K
|
-$1.25 M
|
-$1.70 K
|
-$890.40 K
|
| Income Before Tax |
-$1.98 M
|
-$12.17 M
|
-$16.50 M
|
-$11.95 M
|
-$2.86 M
|
-$5.45 M
|
-$5.15 K
|
-$6.66 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$5.77 K
|
| Net Income |
-$1.98 M
|
-$12.17 M
|
-$16.50 M
|
-$11.95 M
|
-$2.86 M
|
-$5.45 M
|
-$5.15 K
|
-$6.66 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-26.3 |
-3.2 |
-8.4 |
-8.1 |
-5.9 |
-4.9 |
-329.9 |
-5.7 |
| EPS Diluted |
-26.3 |
-3.2 |
-8.4 |
-8.1 |
-5.9 |
-4.9 |
-329.9 |
-5.7 |
| Weighted Average Shares Out |
$75.30 K
|
$3.82 M
|
$1.97 M
|
$1.47 M
|
$481.93 K
|
$1.11 M
|
$16.00
|
$1.18 M
|
| Weighted Average Shares Out Diluted |
$154.33 K
|
$3.82 M
|
$1.97 M
|
$1.47 M
|
$481.93 K
|
$1.11 M
|
$16.00
|
$1.18 M
|
| Link |
|
|
|
|
|
|
|
|
